These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34254325)

  • 21. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
    Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
    PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.
    Wang W; Wang M; Wang L; Adams TS; Tian Y; Xu J
    Sci Rep; 2014 May; 4():5012. PubMed ID: 24852453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.
    Lughezzani G; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Fossati N; Lista G; Larcher A; Abrate A; Mistretta A; Bini V; Palou Redorta J; Graefen M; Guazzoni G
    Eur Urol; 2014 Nov; 66(5):906-12. PubMed ID: 24361258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients.
    Huang YP; Lin TP; Cheng WM; Wei TC; Huang IS; Fan YH; Lin CC; Huang EYH; Chung HJ; Kuo JY; Wu HHH; Lu SH; Chang YH; Lin ATL; Huang WJS
    J Chin Med Assoc; 2019 Nov; 82(11):835-839. PubMed ID: 31425303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.
    Lazzeri M; Briganti A; Scattoni V; Lughezzani G; Larcher A; Gadda GM; Lista G; Cestari A; Buffi N; Bini V; Freschi M; Rigatti P; Montorsi F; Guazzoni G
    J Urol; 2012 Oct; 188(4):1137-43. PubMed ID: 22901578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study.
    Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park JY; Shin TY; Kim JH
    Investig Clin Urol; 2020 Jan; 61(1):42-50. PubMed ID: 31942462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.
    Abrate A; Lazzeri M; Lughezzani G; Buffi N; Bini V; Haese A; de la Taille A; McNicholas T; Redorta JP; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Freschi M; Guazzoni G
    BJU Int; 2015 Apr; 115(4):537-45. PubMed ID: 25130593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
    Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
    Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.
    Huang YQ; Sun T; Zhong WD; Wu CL
    Am J Clin Exp Urol; 2014; 2(4):343-50. PubMed ID: 25606581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1.
    Tan LG; Tan YK; Tai BC; Tan KM; Gauhar V; Tiong HY; Hawkins RC; Thamboo TP; Hong FS; Chiong E
    Asian J Androl; 2017; 19(3):286-290. PubMed ID: 26908062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
    Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
    BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of the prostate health index in a predictive model of prostate cancer.
    Sanchís-Bonet A; Barrionuevo-González M; Bajo-Chueca AM; Pulido-Fonseca L; Ortega-Polledo LE; Tamayo-Ruiz JC; Sánchez-Chapado M
    Actas Urol Esp (Engl Ed); 2018; 42(1):25-32. PubMed ID: 28811062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography.
    Yu GP; Na R; Ye DW; Qi J; Liu F; Chen HT; Wu YS; Zhang GM; Sun JL; Zhu Y; Huang LQ; Ren SC; Jiang DK; Zheng SL; Jiang HW; Sun YH; Ding Q; Xu J
    Asian J Androl; 2016; 18(4):633-8. PubMed ID: 26975483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.
    Hirama H; Sugimoto M; Ito K; Shiraishi T; Kakehi Y
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):257-63. PubMed ID: 24352745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer.
    Filella X; Foj L; Augé JM; Molina R; Alcover J
    Clin Chem Lab Med; 2014 Sep; 52(9):1347-55. PubMed ID: 24695041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
    Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
    J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
    Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
    Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection.
    Barisiene M; Bakavicius A; Stanciute D; Jurkeviciene J; Zelvys A; Ulys A; Vitkus D; Jankevicius F
    Biomed Res Int; 2020; 2020():9872146. PubMed ID: 32775459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.